Oxford Asset Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Oxford Asset Management’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-13,265	Closed	-$141K	–	915
2016 Q2	$141K	Buy	+13,265	New	+$261K	﹤0.01%	718
2015 Q4	–	Sell	-1,570	Closed	-$72K	–	996
2015 Q3	$72K	Buy	+1,570	New	+$59.2K	﹤0.01%	607
2015 Q1	–	Sell	-5,756	Closed	-$216K	–	798
2014 Q4	$216K	Buy	+5,756	New	+$158K	﹤0.01%	622
2014 Q2	–	Sell	-2,901	Closed	-$107K	–	825
2014 Q1	$107K	Sell	2,901 -2,004	-41%	-$76K	﹤0.01%	615
2013 Q4	$203K	Buy	+4,905	New	+$192K	0.01%	646

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Oxford Asset Management's NAVB Position: Q3 2016 in Review

Oxford Asset Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2016, closing a stake of 13,265 shares — an estimated $141K sold.

Oxford Asset Management first reported a position in NAVB in Q4 2013 and held it in 5 quarters. The position peaked at $216K in Q4 2014. 55 funds tracked by Wall St. Rank hold NAVB as of Q3 2016.

Oxford Asset Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
Oxford Asset Management sold 13,265 Navidea Biopharmaceuticals Inc. shares in Q3 2016, an estimated $141K.
Oxford Asset Management first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2013 and held it in 5 quarters.
Oxford Asset Management's Navidea Biopharmaceuticals Inc. position peaked at $216K in Q4 2014.
55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2016.

Based on Oxford Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.